Sign up
Pharma Capital

Bulls, Bears & Brokers: Alto Capital's Tony Locantro on new financial year strategy 1/2

In Part One of a two-part special, Alto Capital's Tony Locantro speaks to Proactive Investors' Danielle Doporto about the end of financial year (EOFY) fallout on stock markets, and his fresh financial year strategy.

"We always have the notion of Tax Loss Selling in June and the market just became quite lethargic. We had this great run into January, a lot of the small cap stocks just went nuts, and now that’s all slowed down. And what I’ve seen is a lot of these stocks now are having a spike on good news, but there’s no follow-through buying, and to me that indicates that all the momentum’s been sucked out of the small cap sector and we’re in for some tough times. But with tough times I believe comes some opportunity, and a good chance for those that are looking for growth stocks to reset and look at those opportunities... sometimes the best investments are those you don't feel comfortable with," says Locantro.

To hear Tony's Tips regarding promising sectors and stocks, watch our video interview.

 

View full . profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.